Kura Oncology Q4 net loss widens on higher R&D spend

-2.02% Post

Kura Oncology, Inc.

KURA

8.26

-2.02%

0.00% Post

Overview

Biopharmaceutical firm reported $2.1 mln in Q4 net product revenue from KOMZIFTI launch
Company's Q4 net loss widened to $81 mln, driven by increased R&D expenses
Kura Oncology maintains strong cash position, expected to fund operations into late 2027

Outlook

Kura anticipates topline Phase 3 results for ziftomenib in 2028

Result Drivers

KOMZIFTI LAUNCH - KOMZIFTI generated $2.1 mln in Q4 revenue, with rapid payer coverage and positive market feedback supporting its adoption in R/R NPM1-m AML

Company press release: ID:nGNX680pl7

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Collaboration Revenue		$2.13 mln
Q4 EPS		-$0.92
Q4 Net Income		-$81 mln
Q4 Operating Expenses		$103.60 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kura Oncology Inc is $28.00, about 227.5% above its March 4 closing price of $8.55

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.